Chrysos Corporation Ltd (C79)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 7.280 |
|---|---|
| 52-week range | 5.180 – 10.130 |
| Return, 1 month / 3 months | +11.1% / +26.6% |
| Return, 1 year / 3 years | −11.8% / +14.1% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 48.5% |
| Worst drawdown (1 year) | -46.7% |
| Average daily value traded | 2.40M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Chrysos Corporation provides mineral analysis technology to the mining industry. Its PhotonAssay system uses high-energy X-rays to measure gold and other elements in drill core, ore and concentrate samples quickly and without the chemical digestion steps used in traditional fire assay. Mining companies and commercial assay laboratories use the service to test samples at mine sites and dedicated facilities. The company is based in Australia and serves customers in gold-producing regions around the world.
Chrysos Corporation Ltd trades under the code C79 on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Chrysos Corporation Ltd (C79) trades on the Australian Securities Exchange in Australia. It last closed at AUD 7.280 on 22 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 329 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 11.8% and over the last three months it rose 26.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 4.4% | ||
| From 52-week high | -26.8% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 26.6% | ||
| 6-month return | -5.0% | ||
| 12-month return, skipping the last month | -20.6% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 48.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.7% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 2.40M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +7.1% |
|---|---|
| 1 month | +11.1% |
| 3 months | +26.6% |
| 6 months | −5.0% |
| 1 year | −11.8% |
| 3 years | +14.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 6.950 / 6.971 |
|---|---|
| Golden / death cross (60 days) | Death, 1 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.314 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.